Sana Biotechnology Advances Diabetes and Cancer Therapies with Mayo Clinic Deal — Sana Biotechnology, Inc.

Event summary

Sana Biotechnology announced a strategic collaboration with Mayo Clinic, including a $25 million equity investment, to advance SC451, a stem cell-derived therapy for type 1 diabetes.
Positive 14-month clinical results for UP421, an allogeneic islet cell therapy, showed survival and function without immunosuppression.
Sana expects to begin Phase 1 trials for SC451 and SG293, a CD8-targeted fusosome for non-Hodgkin lymphoma, later in 2026.
Q1 2026 cash position of $101.1 million, with a pro forma cash position of $128.9 million, provides runway into 2027.

The big picture

Sana Biotechnology's collaboration with Mayo Clinic underscores the growing trend of biotech companies leveraging academic partnerships to accelerate therapeutic development. The focus on stem cell-derived therapies and in vivo CAR T cells aligns with broader industry shifts toward more targeted and scalable treatments for chronic diseases and cancers. With a strengthened cash position and key clinical milestones on the horizon, Sana is positioning itself to compete in high-stakes therapeutic areas.

What we're watching

Clinical Progress: The pace at which Sana can transition SC451 and SG293 into Phase 1 trials will determine its ability to maintain momentum in the competitive diabetes and oncology markets.
Financial Sustainability: Whether Sana's current cash runway and strategic investments will be sufficient to support its ambitious clinical pipeline through 2027.
Partnership Impact: How the collaboration with Mayo Clinic will accelerate the development and standardization of SC451, potentially differentiating it in the type 1 diabetes treatment landscape.